Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Levocarnitine · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Nelfinavir mesylate | DRUG | - |
| Levocarnitine | DRUG | - |
| Adefovir dipivoxil | DRUG | - |
| Saquinavir | DRUG | - |
| Lamivudine | DRUG | - |
| Stavudine | DRUG | - |
| Zidovudine | DRUG | - |
| Indinavir sulfate | DRUG | - |
Inclusion Criteria Patients must have: * Laboratory diagnosis of HIV infection (positive HIV antibody test confirmed by Western blot, p24 antigen assay, HIV-1 RNA, or HIV-1 culture). * An HIV-1 RNA plasma titer \>= 5000 copies/ml within 14-21 days prior to the baseline visit. * CD4 cell count \>= ...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Levocarnitine is a small molecule drug that Gilead Sciences, Inc. is developing for HIV Infections. It has been studied in Phase 2 clinical trials as part of combination anti-HIV treatment regimens. It is an investigational agent in this program rather than an approved therapy for HIV.
Levocarnitine is being developed by Gilead Sciences, Inc., which trades on the Nasdaq under the ticker GILD. The company sponsored the Phase 2 HIV studies of the drug. Gilead is the developer associated with this asset in the HIV Infections program.
Levocarnitine is in Phase 2 development for HIV Infections. Two Phase 2 trials have been conducted, and both are now completed, with no active trials currently listed. The program enrolled a total of 220 patients across those studies.
Levocarnitine has been studied in two completed Phase 2 trials: NCT00002379, which enrolled 100 patients, and NCT00002184, which enrolled 120 patients. Both trials were conducted in the United States and Puerto Rico in HIV-infected patients aged 16 years and older.
The two Phase 2 trials evaluated levocarnitine-containing combination therapy in HIV-infected patients. NCT00002379 examined a regimen including adefovir dipivoxil plus indinavir combined with zidovudine, lamivudine, or stavudine in patients who had not previously taken anti-HIV drugs. NCT00002184 was a stratified, randomized, double-blind study of two dose levels in triple combination therapy.
A total of 220 patients were enrolled across the two completed Phase 2 trials of levocarnitine. NCT00002379 enrolled 100 patients and NCT00002184 enrolled 120 patients. Both studies were conducted in HIV-infected patients aged 16 years and older in the United States and Puerto Rico.